Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here's were VRA comes into play with INTERFERON With SARS
Among the promising drugs that have been tested, interferon alpha is especially interesting, the director of the National Institute of Allergies and Infectious Diseases told members of Congress a week ago. An interferon alpha nasal spray was shown to be effective during research in the 1980's against colds caused by the coronavirus, but the research was abandoned because of excessive irritation. But in the face of SARS, the side effects could become acceptable.
Over 50 million shares traded today on VRA Amex Exchange
Here's were VRA comes into play with INTERFERON With SARS
Among the promising drugs that have been tested, interferon alpha is especially interesting, the director of the National Institute of Allergies and Infectious Diseases told members of Congress a week ago. An interferon alpha nasal spray was shown to be effective during research in the 1980's against colds caused by the coronavirus, but the research was abandoned because of excessive irritation. But in the face of SARS, the side effects could become acceptable.
Over 50 million shares traded today on VRA Amex Exchange
Here's were VRA comes into play with INTERFERON
Among the promising drugs that have been tested, interferon alpha is especially interesting, the director of the National Institute of Allergies and Infectious Diseases told members of Congress a week ago. An interferon alpha nasal spray was shown to be effective during research in the 1980's against colds caused by the coronavirus, but the research was abandoned because of excessive irritation. But in the face of SARS, the side effects could become acceptable.
Here's were VRA comes into play with INTERFERON
Among the promising drugs that have been tested, interferon alpha is especially interesting, the director of the National Institute of Allergies and Infectious Diseases told members of Congress a week ago. An interferon alpha nasal spray was shown to be effective during research in the 1980's against colds caused by the coronavirus, but the research was abandoned because of excessive irritation. But in the face of SARS, the side effects could become acceptable.
"INTERFERON" research
http://www.usatoday.com/news/health/2003-04-22-sars-drugs_x.htm
http://www.jsonline.com/alive/ap/apr03/ap-sars-virus-trea042203.asp?format=print
http://cooltech.iafrica.com/science/229961.htm
http://www.journalnow.com/wsj/nationworld/MGBZWT6PUED.html
http://www.azcentral.com/arizonarepublic/news/articles/0423sars23.html
Just keep the chit down there we don't need it out west.
GENVEC INC (U-GNVC) - News Release
GenVec and National Institutes of Health Begin Work on SARS Vaccine
GAITHERSBURG, Md., April 24 /PRNewswire-FirstCall/ -- GenVec, Inc. , a biopharmaceutical company, announced today that it has signed an expansion to its existing agreement with the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (VRC/NIAID/NIH), which is directed to HIV-1 vaccine development, to also allow the VRC/NIAID/NIH and GenVec to begin development of a clinical grade vaccine against Severe Acute Respiratory Syndrome (SARS) using GenVec's adenovector technology.
Under the contract amendment, issued and managed by SAIC of Frederick, Inc., GenVec will receive $420,000 and will be responsible for constructing and producing clinical grade adenovector-based vaccine candidates against SARS. The VRC/NIAID/NIH will test the vaccine candidates in preclinical models to assess safety and efficacy. Clinical trials in humans could commence following successful preclinical testing results.
"The VRC/NIAID/NIH and GenVec are responding rapidly to this emerging public health threat," commented Dr. C. Richter King, GenVec's Vice President, Research. He continued, "Our technology is highly versatile and allows us to rapidly address a variety of global health threats, as highlighted by our existing vaccine programs for HIV, malaria and dengue virus infections. The existence of our HIV vaccine development program and our productive relationship with the VRC/NIAID/NIH, has allowed GenVec to move quickly to address a newly defined infectious target, such as SARS, without having to significantly redirect company resources."
SARS is an emerging health threat that is believed to have originated in China, with cases now being reporting in more than 25 countries including the United States. It is highly contagious, with more than 4,400 reported cases worldwide, and inflicts a risk of death estimated at 6% of those infected. The agent that purportedly causes the disease, from the Coronavirus family, has been identified. The recently completed sequence of the SARS Coronavirus genome will be used by the VRC/NIAID/NIH and GenVec to develop preventative adenoviral vector vaccine candidates.
GenVec is a publicly-held biopharmaceutical company focused on the development and commercialization of products that produce medically beneficial proteins at the site of disease. The Company combines its patented gene transfer technologies with proprietary therapeutic genes to create product candidates, such as TNFerade(TM) for cancer, BIOBYPASS(R) for heart disease, and AdPEDF for macular degeneration. The Company is also collaborating with the U.S. government for the development of therapeutic vaccine candidates for HIV, malaria, dengue virus, and SARS. Additional information on GenVec is available at its web site located at http://www.genvec.com/, and in the Company's various filings with the Securities and Exchange Commission.
Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward- looking statements within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements are typically identified by words or phrases such as "believe," "expect," "anticipate," "intend," "estimate," "assume," "plan," "outlook," "prospect," and variations of such words and similar expressions, or future or conditional verbs such as "will," "would," "should," "could," "may," or similar expressions. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. The following factors, among others, could cause actual results to differ materially from forward-looking statements or historical experience: risks relating to the early stage of product candidates under development, risks relating to GenVec's ability to identify and enter into agreements with potential collaborative partners, uncertainties relating to clinical trials, dependence on third parties, future capital needs, and risks relating to the commercialization, if any, of GenVec's proposed product candidates (such as marketing, regulatory, patent, product liability, supply, competition and other risks). GenVec's SEC reports identify additional factors that can affect forward-looking statements. These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.
GenVec, Inc.
CONTACT: Ginny Dunn, Corporate Communications of GenVec, Inc.,
+1-301-944-1172, or gdunn@genvec.com
Web site: http://www.genvec.com/
What action on AVII
C-Ya's
50 million on vra
CNBC hyping AVII :)
Hot sector going up
Holding mine till after hours any way
in avii 6.83
Better to sit on the sidelines if results don't meet market expectations we all know what happens.
If there good you can always buy and then the risk is out of the way.
West Nile virus avii that will be hot too this summer
SWG
Better have the goods or tank city
Key words MAYBE
What you want me too LOL
lol
Now if you put that extra cash into VRA you will become an instant Million next week>LOL
Yup Speculation but must have something behind it cause there all gone too meetings.we see
Called VRA all out at meetings today back monday
Full article on SARS
By DANIEL Q. HANEY
Wed, April 23, 2003
(AP) - Scientists in search of a SARS cure have narrowed their focus to several dozen drugs that appear to have the best chance of stopping the deadly respiratory virus, but they have abandoned plans to test one of them in people.
The urgent hunt for something that works - preferably a medicine already on the market or close to it - was helped by the breakthrough a week ago in decoding the virus's genetic makeup, which gives scientists some logical targets.
While they cannot predict when they will find a treatment, they should know soon if an effective medicine is likely to be in hospitals quickly. If none in testing shows promise in the next few weeks, a treatment may have to be created from scratch, a process that could take at least five years.
For now, SARS treatment amounts to keeping patients isolated and dealing with their symptoms while the infection runs its course.
The drug ribavirin is being used by doctors in Hong Kong and Toronto who are convinced it helps many SARS patients. But U.S. researchers, who have been skeptical all along, shelved a plan to formally test the drug with a careful experiment in people.
The decision was made this week after testing at the U.S. Army Medical Research Institute for Infectious Diseases at Fort Detrick, Md., found no evidence that the drug has any effect against SARS virus growing in tissue cultures.
Dr. Catherine Laughlin, virology chief at the National Institute of Allergy and Infectious Diseases, said there was simply no evidence it worked. "It has significant toxicity, and there was a real chance you could do more harm than good."
Viruses are much harder to kill than bacteria, and only three dozen antiviral medicines are on the market. None is specifically aimed at the coronaviruses, the family that includes the SARS virus as well as some that cause common colds.
Laughlin said ribavirin is the only drug conclusively shown ineffective in the army experiments so far, and lab testing is underway or will begin this week on all the other antiviral drugs on the market. These are 16 AIDS drugs, 13 herpes drugs and seven aimed at flu and other viruses. Also to be tested are seven forms of interferon, which are the body's natural microbe killers.
Thanks Jim
Full article on SARS
By DANIEL Q. HANEY
Wed, April 23, 2003
(AP) - Scientists in search of a SARS cure have narrowed their focus to several dozen drugs that appear to have the best chance of stopping the deadly respiratory virus, but they have abandoned plans to test one of them in people.
The urgent hunt for something that works - preferably a medicine already on the market or close to it - was helped by the breakthrough a week ago in decoding the virus's genetic makeup, which gives scientists some logical targets.
While they cannot predict when they will find a treatment, they should know soon if an effective medicine is likely to be in hospitals quickly. If none in testing shows promise in the next few weeks, a treatment may have to be created from scratch, a process that could take at least five years.
For now, SARS treatment amounts to keeping patients isolated and dealing with their symptoms while the infection runs its course.
The drug ribavirin is being used by doctors in Hong Kong and Toronto who are convinced it helps many SARS patients. But U.S. researchers, who have been skeptical all along, shelved a plan to formally test the drug with a careful experiment in people.
The decision was made this week after testing at the U.S. Army Medical Research Institute for Infectious Diseases at Fort Detrick, Md., found no evidence that the drug has any effect against SARS virus growing in tissue cultures.
Dr. Catherine Laughlin, virology chief at the National Institute of Allergy and Infectious Diseases, said there was simply no evidence it worked. "It has significant toxicity, and there was a real chance you could do more harm than good."
Viruses are much harder to kill than bacteria, and only three dozen antiviral medicines are on the market. None is specifically aimed at the coronaviruses, the family that includes the SARS virus as well as some that cause common colds.
Laughlin said ribavirin is the only drug conclusively shown ineffective in the army experiments so far, and lab testing is underway or will begin this week on all the other antiviral drugs on the market. These are 16 AIDS drugs, 13 herpes drugs and seven aimed at flu and other viruses. Also to be tested are seven forms of interferon, which are the body's natural microbe killers.
READ this on VRA
Laughlin said ribavirin is the only drug conclusively shown ineffective in the army experiments so far, and lab testing is underway or will begin this week on all the other antiviral drugs on the market. These are 16 AIDS drugs, 13 herpes drugs and seven aimed at flu and other viruses. Also to be tested are seven forms of interferon, which are the body's natural microbe killers.
READ this on VRA
Laughlin said ribavirin is the only drug conclusively shown ineffective in the army experiments so far, and lab testing is underway or will begin this week on all the other antiviral drugs on the market. These are 16 AIDS drugs, 13 herpes drugs and seven aimed at flu and other viruses. Also to be tested are seven forms of interferon, which are the body's natural microbe killers.
VRA-- What is Natural Interferon?
Produced by leukocytes (white blood cells), natural interferon helps improve the body's natural resistance against disease. It is one of the body's natural defensive responses to foreign substances such as viruses, and is so named because it "interferes" with viral growth.
ADDED more at .13
LOL too much volume here for nothing going on
vra 33 mil shares traded here already
VIT sister company to BGO watch it I hear the promo will come at some point
Lor will rock if they got cure time will tell
Good call
Remember All stocks chit till you find a good one.LOL
Ok I'm a penny player Gambler so I'm in VRA for this Sars rumour.
Trading huge volume is a good thing
Time will tell
VRA the next SARS STOCK weeeeeeeeeeeeeeeeeee
Marcos you believe what you like.
I have stated long ago that was not me.
You continue to accuse.
Roughneck has nothing to do with were I work and not even a part of any job discription were I work.
Yes GTT is where everything got started
Weather your Taco I have no clue but it did fit your stile
So if your not I apologize.
Since this will go nowhere with you anyways it will be my last post on this.
Gold will run till June after that its summer
Wonder who got me suspended today!LOL
Maybe read your thread on SI then you will know why.
First of all You started the BS on my thread.Sure I was posting on your thread so big deal.Who was I bothering?You attack me on my thread so thats when it started.
I don't have 5,10,15,20,30 0r 100 different names like you claim I do.
I have Rocketred here and SI
I have Rocket1 and Rocketred1000(Private Thread)on SH(and most know this as I told them)
This has gone on long enough and it all started with GTT in which that was the Chief's deal not mine or Bigbuk.
What ever happened there has nothing to do with me at all.
I don't front run stocks I never have.
When I buy I buy I don't sit there for a month trying to buy and then pump it thats front running your own chit.
So what ever you like to believe you believe I can't change that.
PS I have the right to short any stock I like.It just so happens you own some of them and I will continue to short any stock I like.CDNX stocks are not hard to pick for shorting.